Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

This study is testing a combination of two drugs — efineptakin alfa (a growth factor that helps brain cells survive) and pembrolizumab (an immunotherapy) — for people with recurrent glioblastoma, the most aggressive form of brain tumor, whose cancer has grown back after standard treatment. **You may be eligible if...** - You are 18 or older with recurrent or progressive glioblastoma (WHO Grade IV IDH wildtype) - You have previously received surgery, radiation, and temozolomide chemotherapy - Your tumor is visible on MRI and can be surgically removed again - Your overall health is adequate for treatment (ECOG 0–2) **You may NOT be eligible if...** - You have had prior immunotherapy for your brain tumor - You have active autoimmune disease or are on immunosuppressive steroids - You are pregnant or breastfeeding - Your tumor has certain molecular features (e.g., IDH mutation) Talk to your doctor to see if this trial is right for you.